Rossmore Private Capital’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.9M | Sell |
20,769
-1
| -0% | -$1.02K | 2.01% | 13 |
|
|
2026
Q1 | $19.1M | Sell |
20,770
-172
| -0.8% | -$174K | 1.68% | 15 |
|
|
2025
Q4 | $22.5M | Buy |
20,942
+249
| +1% | +$238K | 2% | 12 |
|
|
2025
Q3 | $15.8M | Buy |
20,693
+193
| +0.9% | +$144K | 1.7% | 13 |
|
|
2025
Q2 | $16M | Sell |
20,500
-43
| -0.2% | -$33.4K | 1.87% | 9 |
|
|
2025
Q1 | $17M | Buy |
20,543
+934
| +5% | +$777K | 2.09% | 9 |
|
|
2024
Q4 | $15.2M | Buy |
19,609
+461
| +2% | +$382K | 1.87% | 10 |
|
|
2024
Q3 | $17M | Buy |
19,148
+34
| +0.2% | +$30.6K | 2.1% | 9 |
|
|
2024
Q2 | $17.3M | Buy |
19,114
+359
| +2% | +$287K | 2.27% | 8 |
|
|
2024
Q1 | $14.6M | Buy |
18,755
+1,355
| +8% | +$964K | 1.91% | 9 |
|
|
2023
Q4 | $10.1M | Buy |
17,400
+80
| +0.5% | +$46.7K | 1.43% | 13 |
|
|
2023
Q3 | $9.3M | Sell |
17,320
-58
| -0.3% | -$29.9K | 1.41% | 13 |
|
|
2023
Q2 | $8.15M | Sell |
17,378
-35
| -0.2% | -$14.7K | 1.21% | 17 |
|
|
2023
Q1 | $5.98M | Buy |
17,413
+250
| +1% | +$84.3K | 0.93% | 30 |
|
|
2022
Q4 | $6.28M | Buy |
17,163
+16
| +0.1% | +$5.67K | 1.01% | 28 |
|
|
2022
Q3 | $5.54M | Buy |
17,147
+45
| +0.3% | +$14.3K | 0.99% | 27 |
|
|
2022
Q2 | $5.54M | Buy |
17,102
+250
| +1% | +$75K | 0.96% | 27 |
|
|
2022
Q1 | $4.83M | Buy |
16,852
+503
| +3% | +$129K | 0.75% | 35 |
|
|
2021
Q4 | $4.52M | Buy |
16,349
+65
| +0.4% | +$16.5K | 0.71% | 40 |
|
|
2021
Q3 | $3.76M | Sell |
16,284
-191
| -1% | -$47.1K | 0.64% | 43 |
|
|
2021
Q2 | $3.78M | Buy |
16,475
+301
| +2% | +$60.5K | 0.65% | 43 |
|
|
2021
Q1 | $3.02M | Buy |
16,174
+1,594
| +11% | +$312K | 0.57% | 46 |
|
|
2020
Q4 | $2.46M | Buy |
14,580
+207
| +1% | +$30.9K | 0.5% | 52 |
|
|
2020
Q3 | $2.13M | Buy |
14,373
+2,565
| +22% | +$397K | 0.5% | 53 |
|
|
2020
Q2 | $1.94M | Buy |
11,808
+1,512
| +15% | +$232K | 0.54% | 47 |
|
|
2020
Q1 | $1.43M | Buy |
10,296
+81
| +0.8% | +$11.1K | 0.49% | 52 |
|
|
2019
Q4 | $1.34M | Hold |
10,215
| – | – | 0.41% | 50 |
|
|
2019
Q3 | $1.14M | Buy |
10,215
+2,800
| +38% | +$312K | 0.38% | 53 |
|
|
2019
Q2 | $822K | Hold |
7,415
| – | – | 0.29% | 61 |
|
|
2019
Q1 | $962K | Buy |
7,415
+300
| +4% | +$36.5K | 0.35% | 50 |
|
|
2018
Q4 | $823K | Hold |
7,115
| – | – | 0.35% | 53 |
|
|
2018
Q3 | $764K | Buy |
7,115
+2,245
| +46% | +$224K | 0.31% | 57 |
|
|
2018
Q2 | $416K | Buy |
+4,870
| New | +$400K | 0.27% | 69 |
|
|
2018
Q1 | – | Sell |
-1,289
| Closed | -$109K | – | 277 |
|
|
2017
Q4 | $109K | Buy |
+1,289
| New | +$110K | 0.11% | 124 |
|
Other funds holding LLY
Rossmore Private Capital's LLY Position: Q2 2026 in Review
Rossmore Private Capital reduced its Eli Lilly (LLY) stake by 0% in Q2 2026, selling an estimated $1.02K and leaving 20,769 shares worth $24.9M. The position accounts for 2.01% of the portfolio, ranked #13.
Rossmore Private Capital first reported a position in LLY in Q4 2017 and has held it in 34 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Rossmore Private Capital held 20,769 shares of Eli Lilly worth $24.9M as of Q2 2026.
- Rossmore Private Capital sold 1 Eli Lilly share in Q2 2026, an estimated $1.02K.
- Eli Lilly made up 2.01% of Rossmore Private Capital's portfolio in Q2 2026, its #13 holding.
- Rossmore Private Capital first reported a position in Eli Lilly in Q4 2017 and has held it in 34 quarters since.
- 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Rossmore Private Capital's 13F filing for Q2 2026, filed 31 Jul 2026.